There is now a large body of data indicating that the cannabinoid receptor type 2 (CB 2 ) is linked to a variety of immune events. This functional relevance appears to be most salient in the course of inflammation, a process during which there is an increased number of receptors that are available for activation. Studies aimed at elucidating signal transduction events resulting from CB 2 interaction with its native ligands, and of the role of exogenous cannabinoids in modulating this process, are providing novel insights into the role of CB 2 in maintaining a homeostatic immune balance within the host. Furthermore, these studies suggest that the CB 2 may serve as a selective molecular target for therapeutic manipulation of untoward immune responses, including those associated with a variety of neuropathies that exhibit a hyperinflammatory component.
Cannabinoids are highly lipophilic molecules that have been shown to alter the functional activities of immune cells in vitro and in vivo. The term 'exogenous cannabinoids' describes cannabinoids that are extracted from the marijuana plant Cannabis sativa or are synthesised in the laboratory. The marijuana cannabinoids delta-9-tetrahydrocannabinol (D 9 -THC), cannabinol (CBN) and cannabidiol (CBD) have been the most studied exogenous cannabinoids. D 9 -THC acts as a partial receptor agonist: on binding to cannabinoid receptors it elicits a response that never reaches the maximum efficacy. This compound is the major psychoactive and immunomodulatory component in marijuana and primarily exerts immunosuppressive effects on immune cells at peripheral sites and within the central nervous system (CNS). Synthetic exogenous cannabinoids that have been used widely in research include CP55940, WIN55212-2, SR141716A and SR144528 (Fig. 1 ). CP55940 and WIN55212-2 are full receptor agonists: on binding to cannabinoid receptors they elicit responses that garner maximum efficacy.
Endocannabinoids ('endogenous cannabinoids') constitute a second group of cannabinoids; these are found natively in vertebrate systems and are Endocannabinoids are derivatives of integral components of cellular membranes and act as hydrophobic lipid messengers. As a result of their hydrophobicity, these molecules are not able to translocate in aqueous environments and, upon release, activate cannabinoid receptors locally or on nearby cells. Within the CNS, these bioactive lipids act as synaptic modulators (retrograde messengers); however, unlike other synaptic messengers such as the neurotransmitters acetylcholine and dopamine, endocannabinoids are not presynthesised and stored in vesicles but are produced 'on demand'.
The first endocannabinoid to be identified was arachidonoylethanolamide (AEA; anandamide), which was isolated from porcine brain (Ref. 6) . AEA is the amide component of arachidonic acid and ethanolamine. The second endocannabinoid to be identified was 2-arachidonoylglycerol (2-AG), which was isolated from canine gut (Ref. 7). 2-AG is an ester derivative of arachidonic acid and glycerol, and is synthesised from the hydrolysis of 1,2-diacylglycerol (DAG) by a DAG lipase. In the brain, 2-AG is more bioactive and abundant than AEA. Both AEA and 2-AG are transported across the cell membrane before being degraded by fatty acid amide hydrolase (FAAH), although 2-AG can also be degraded by monoacylglycerol lipase (MGL), a serine hydrolase (Refs 8, 9, 10). Several reports suggest that transport across cellular membranes is facilitated by carrier proteins, which have yet to be fully identified (Refs 11, 12, 13, 14) . In addition, while cannabinoid receptors serve as the molecular targets of AEA and 2-AG, it has been reported that these two compounds also can exert their effects in a receptorindependent fashion (Refs 15, 16, 17, 18).
Cannabinoid receptors CB 1
The initial evidence for the existence of acannabinoid receptor came from pharmacological studies. Treatment of neuroblastoma cells with D
9
-THC, or with the synthetic compounds levonantradol and desacetyllevonantradol, resulted in inhibition of plasma membrane activity of adenylate cyclase, the enzyme that catalyses the conversion of ATP to cyclic AMP (cAMP) and pyrophosphate (Refs 19, 20) . However, in contrast to levonantradol, dextronantradol was shown to have no effect on this activity, indicating that the inhibition was stereoselective -a requisite condition for a receptor-mediated action. Additional studies demonstrated that the putative cannabinoid receptor was coupled to an inhibitory guanine-nucleotide-binding complex (G i/o ), because treatment with pertussis toxin reversed the inhibitory effect on adenylate cyclase (Ref. 21). Radioligand binding assays and in situ mRNA hybridisation demonstrated that the receptor was distributed throughout the brain and was localised predominantly to the cerebellum, cerebral cortex, hippocampus, basal ganglia and spinal cord (Refs 6, 22, 23, 24). Subsequently, the gene encoding the receptor (CNR1) was isolated and cloned from a rat brain cDNA library (Ref. 22), revealing the sequence for a 473 amino acid long, seven-transmembrane G-protein-coupled protein with an extracellular, glycosylated N-terminus and an intracellular C-terminus (Fig. 2a) . This receptor was referred to initially as the 'neuronal' or 'central' cannabinoid receptor and has since been designated cannabinoid receptor 1 (CB 1 ).
CB 1 inhibits the phosphorylation of A-type potassium channels through the coupled inhibitory G protein (G i/o ), as explained in further detail below in the cannabinoid receptor signalling section. Inhibition of the phosphorylation of A-type potassium channels results in continuous potassium currents that may prevent neurotransmission (Refs 25, 26) . N-type calcium channels also are inhibited by CB 1 through direct interaction with the inhibitory G protein (G i/o ). CB 1 -mediated restriction of neurotransmission via potassium and calcium channels accounts for cognitive impairment and sedative-like effects experienced by marijuana users (Refs 26, 27).
CB 2
Following the identification of CB 1 , a 'peripheral' or 'non-neuronal' cannabinoid receptor was cloned from a human promyelocytic cell line (HL60) cDNA library, and was designated cannabinoid receptor 2 (CB 2 ) (Ref. 28). The gene for this receptor (CNR2) was shown to encode a 360 amino acid long, seven-transmembrane G-protein-coupled receptor ( Fig. 2b) with, like CB 1 , an extracellular, glycosylated N-terminus and an intracellular C-terminus. Unlike CB 1 , there is a considerable level of sequence variation for CB 2 among human, mouse and rat species, particularly when comparing rat and human sequences. There is 81% amino acid identity between rat and human CB 2 , as compared with 93% amino acid identity between rat and mouse CB 2 
Cannabinoid receptor signalling
Both CB 1 and CB 2 are involved in activating signalling cascades that include adenylate cyclase and cAMP, mitogen-activated protein kinase (MAPK), and modulation of levels of intracellular calcium (Refs 26, 53, 54, 55, 56) . Upon cannabinoid receptor interaction with its cognate ligand, the receptor-coupled G protein exchanges the inactive guanine nucleotide GDP for its active form GTP, and the heterotrimeric G protein dissociates into a and bg subunits (Fig. 3a) . The bg subunits are thought to take part in signalling pathways distinct from those of the a subunit, such as the regulation of phospholipase C (PLC) isoforms and activation of the MAPK signalling network (Ref. 25) (Fig. 3b) . CB 2 partly exerts its effects through initiation of phospholipase C (PLC) and inositol 1,4,5-trisphosphate (IP 3 ) signalling pathways that result in increased levels of intracellular calcium (Ref. 56) . The a subunit binds to, and inhibits the activity of, adenylate cyclase, thereby preventing synthesis of the second messenger cAMP and negatively affecting downstream cAMP-dependent signalling events. As a decrease in cAMP production underlies a mechanism in which CB 1 71, 72) . In murine models of granulomatous amoebic encephalitis (GAE) and atherosclerosis, macrophages and macrophagelike cells exposed to D 9 -THC displayed less migration to sites of infection (Refs 73, 74, 75, 76) . Thus, the collective data suggest that exogenous cannabinoids such as D 9 -THC inhibit the functional activities of a variety of immunocytes -an outcome that is consistent with the role of these compounds in decreased host resistance to infectious agents.
Role of CB 2 in cell-mediated and humoral immunity
The recognition that select exogenous cannabinoids acted as anti-inflammatory agents and that immune cells also expressed cannabinoid receptors served as an impetus for studies aimed at defining a functional linkage between these two events. The preponderance of studies to date indicates that the cannabinoid receptor that is linked to modulation of the majority of immune functional responses is CB 2 . Emerging role of the cannabinoid receptor CB
Effects of exogenous cannbinoids
The partial agonist D
9
-THC, as well as the full cannabinoid agonists CP55940 and WIN55212-2, has been reported to enhance human tonsillar B cell growth when used at nanomolar concentrations (Ref. 77 ) by a CB 2 -mediated mechanism. Consistent with these results, the CB 2 -selective antagonist SR144528 reversed the stimulating effects of CP55940 on human tonsillar B cell activation (Ref. 78) . By contrast, several reports have indicated that cannabinoids suppress the antibody response of humans and animals (Refs 79, 80), at least in part through inhibition of adenylate cyclase by a pertussis-toxin-sensitive G-protein-coupled mechanism (Ref. 81). Furthermore, CB 2 was shown to be downregulated at the mRNA and protein levels during B cell differentiation (Ref. 78) . Together, these observations suggest that the CB 2 plays a stimulatory role in B cell activation and growth, while exerting a suppressive role in B cell differentiation and antibody production.
Cannabinoidsalso have beenreported to suppress various activities of Tcells, apparently through CB 2 . For example, in vivo administration of D 9 -THC to mice resulted in significant inhibition of NK cytolytic activity without affecting ConA-induced splenocyte proliferation (Ref. 82) . Concomitant with this inhibition, levels of interferon g (IFN-g) were reduced significantly, and CB 1 and CB 2 antagonists reversed this effect. In view of these observations, it was suggested that both CB 1 and CB 2 were involved in the network that mediates NK cytolytic activity. figure. ) (a) The adenylate cyclase (AC) pathway. G ia signalling downregulates the pro-inflammatory immune response via adenylate cyclase. Upon cannabinoid receptor activation, the a subunit of the G i protein interacts with adenylate cyclase to inhibit its activity. This results in a decrease of cAMP production, which leads to inactivation of protein kinase A (PKA). IkB-a remains unphosphorylated due to PKA inactivation, thus preventing activation, nuclear translocation and DNA binding of NF-kB and other transcription factors. These events ultimately lead to the downregulation of pro-inflammatory mediator gene expression. (b) The mitogen-activated protein kinase (MAPK) pathway. Following cannabinoid receptor activation, the bg subunits of the G i protein induce Ras-dependent MAP kinase signalling pathways, culminating in chemotaxis. The SRC kinase is activated upon interaction with G i bg subunits and phosphorylates tyrosine residues of the EGF receptor. The SHC-SOS-GRB2 trimer binds the EGF receptor via the SHC adaptor protein, while the guanine-nucleotide-exchange factor SOS activates Ras. Following Ras activation, two independent signalling pathways are initiated, leading to the activation of p38 (encoded by MAPK14) and ERK1 and 2 (encoded by the MAPK1 and MAPK2 genes, respectively). p38 as well as ERK1 and 2 can activate JNK, which induces chemotaxis of immune cells. Abbreviations: EGF, epidermal growth factor; ERK, extracellular-signal-regulated kinase; IL, interleukin; iNOS, inducible nitric oxide synthase; JNK, c-jun N-terminal kinase; MEK1 and MEK2, MAPK kinase encoded by MAP2K1 and MAP2K2 genes, respectively; MEKK1, MAPK kinase kinase encoded by MAP3K1 gene; MKK4, MAPK kinase 4 encoded by MAP2K4 gene; RAC1, Ras-related C3 botulinum toxin substrate 1; RAF1, v-Raf-1 murine leukaemia viral oncogenehomologue;SHC,Srchomology2domain-containing;SOS,sonofsevenless;TNF,tumournecrosisfactor. dependent pathway. Collectively, the results from several studies suggest that exogenous cannabinoids elicit a shift from a Th1 proinflammatory cytokine expression profile to a Th2 anti-inflammatory profile, and that CB 2 may be linked to this effect.
Effects of endogenous cannabinoids
Endocannabinoids also have been reported to affect immune function, mostly though CB 2 . The effects of AEA and palmitoylethanolamide, as well as Palmitoylethanolamide, at concentrations similar to those of AEA, inhibited the synthesis of IL-4, IL-6 and IL-8, and the production of p75 TNF-a soluble receptor. However, palmitoylethanolamide did not affect TNF-a and IFN-g production. Neither AEA nor palmitoylethanolamide had an effect on IL-10 synthesis. Based on these observations, it was suggested that various endogenous fatty acid ethanolamides participated in the regulation of the immune response, and that the inhibitory properties of AEA and palmitoylethanolamide were due to activation of CB 2 since it has been shown that palmitoylethanolamide has a high affinity for the CB 2 receptor and does not bind the CB 1 Role of CB 2 in macrophages and macrophage-like cells Although it is now evident that cannabinoids exert a variety of effects on the activities of macrophage and macrophage-like cells, a picture is emerging as to the role of CB 2 in these processes and the state of cell activation under which it is functionally relevant.
Differential expression of CB 2
Macrophages and macrophage-like cells such as microglia undergo a maturation, differentiation and activation process characterised by differential gene expression and the acquisition of correlative distinctive functional capabilities (Refs 102, 103, 104 ). These cells can be driven sequentially in response to multiple signals from 'resting' to 'responsive', 'responsive' to 'primed', and 'primed' to 'fully activated' states, a process that mimics events in vivo. Using in vitro models, it has been shown that levels of CB 2 receptor mRNA and protein are modulated differentially in relation to cell activation state (Ref. 105) . The CB 2 is not detected in resting cells, is present at high levels in responsive and primed cells, and is identified at greatly diminished levels in fully activated cells (Fig. 4) . These observations suggest that the CB 2 is expressed 'on demand' and that the modulation of CB 2 levels is a feature common to cells of macrophage lineage as they participate in the inflammatory response and undergo differential gene expression and acquisition of distinctive functional properties. Furthermore, the relatively high levels of CB 2 recorded for macrophages when in responsive and primed states suggest that these cells, and possibly other immune cell types, exhibit a functionally relevant 'window' of CB 2 expression during which they are most susceptible to cannabinoid-mediated action. Furthermore, since CB 1 is expressed at low and constitutive levels in microglia as compared with CB 2 , the kinetics of expression of the two receptors as linked to immune functional activities may be distinct.
Chemotaxis as a signature activity of 'responsive' macrophages -THC and CP55940 deactivation of migratory responsiveness to the chemokine CCL5, an event that is mediated through activation of the cognate G-proteincoupled chemokine receptor CCR5, suggested that signalling through CB 2 leads to 'cross-talk' between that receptor and CCR5. These and other studies implicate the CB 2 in a network of G-protein-coupled receptor signal transduction systems, inclusive of chemokine receptors, that act co-ordinately to modulate macrophage migration.
Antigen processing as a signature activity of 'primed' macrophages
It has also been shown that CB 2 is involved in cannabinoid-mediated inhibition of processing of antigens by macrophages. In studies examining the effect of D -THC did not affect IL-2 production when the macrophages presented a synthetic peptide of the antigen to T cells, suggesting that the drug interfered with antigen processing, not peptide presentation. The cannabinoid inhibition of the T cell response to native lysozyme was stereoselective, consistent with the involvement of a cannabinoid receptor: bioactive CP55940 diminished T cell activation whereas the relatively inactive stereoisomer CP56667 did not. The macrophage hybridoma expressed mRNA for CB 2 but not for CB 1 Neuroinflammatory disorders: CB 2 as a therapeutic target?
Like macrophages at peripheral sites, microglia are able to phagocytose and process antigens, and upon activation produce pro-inflammatory factors including the cytokines IL-1, IL-6 and TNF-a (Refs 137, 138, 139 ). Pro-inflammatory mediators released from microglia are cytotoxic and also can secondarily activate astrocytes, leading to a further induction of the expression of inflammatory factors. The resultant 'storm' of pro-inflammatory mediators contributes to breakdown of the blood -brain barrier and plays a critical role in promoting influx into the CNS of immunocytes from peripheral nonneuronal sites that also express CB 2 . Microglia are believed to play a major role in many neuropathogenic diseases and disorders such as Alzheimer disease, multiple sclerosis, amyotrophic lateral sclerosis, and HIV (human immunodeficiency virus) encephalitis.
Alzheimer disease
Alzheimer disease is the most common neurodegenerative disorder that causes senile dementia. The defining neuropathological features of the disease are the presence of extracellular neuritic amyloid plaques and intracellular neurofibrillary tangles in the brain; as neurodegeneration progresses, there is accelerated neurofibrillary tangle formation, neuroinflammation and neuronal loss.
It 
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is characterised pathologically by progressive degeneration of cortical motor neurons (upper motor neurons) and clinically by muscle wasting, weakness and spasticity that progresses to complete paralysis (Ref. 156) . A pathological hallmark of amyotrophic lateral sclerosis is neuroinflammmation, a process that is mediated by pro-inflammatory cytokines, prostaglandins and NO (Ref. 157) .
CBN delayed the onset of symptoms in mice suffering from experimentally induced amyotrophic lateral sclerosis without affecting survival (Ref. 158) , and treatment of mice with WIN55212-2 after onset of symptoms delayed overall disease progression (Ref. 159) . Also, the CB 2 agonist AM-1241 prolonged survival in a G93A-SOD1 mutant transgenic mouse model of amyotrophic lateral sclerosis when administered at onset of disease symptoms (Ref. 160) . mRNA and receptor binding of CB 2 were selectively upregulated in spinal cords of these mice in a fashion that paralleled disease progression. Daily injections of AM-1241 initiated at onset of symptoms increased the survival interval after disease onset by 56%. Collectively, the results suggested that the CB 2 agonist extended the interval for motor neuron degeneration and prolonged function in these affected mice.
HIV encephalitis
HIV encephalitis, also known as acquired immune deficiency syndrome (AIDS)-dementia complex, results in progressive memory loss, intellectual deterioration, behavioural changes, and motor deficits (Ref. 161) . The neuropathology of HIVE is characterised by neuronal loss, glial activation, presence of multinucleated giant cells, perivascular mononuclear infiltration, and in some cases vacuolar myelopathy and myelin pallor (Ref. 161) . The production of proinflammatory cytokines such as TNF-a by activated monocytes and microglia, and neurotoxins such as glutamate and NO, is the primary cause of brain damage associated with this disorder. In addition, HIV-specific gene products such as the transactivator Tat and the envelope glycoprotein gp120 that are released from infected monocytes and microglia contribute to neuropathology.
The simian immunodeficiency model comes closest to replicating events that are associated with HIV infection of the human CNS. Examination of brains of macaques with simian immunodeficiency virus (SIV)-induced encephalitis has led to the suggestion that the endocannabinoid system participates in the development of HIV-induced encephalitis (Ref. 162) . In this infectivity model, expression of CB 2 was induced in perivascular macrophages, microglial nodules, and T cells. It was proposed that activation of CB 2, expressed by perivascular macrophages, which play a critical role in viral entry into the CNS (Refs 163, 164 
Summary of cannabinoid receptors in neuropathological disorders
In summary, cannabinoid receptors appear to play an important role in neuropathological diseases. CB 1 has been reported to be critical for the overall homeostatic balance and regulation of the CNS, while CB 2 has been implicated as playing a functionally relevant role during neuroinflammation. Microglia, as resident macrophages in the CNS, not only play a role in host defence and tissue repair but also have been implicated as contributive to, if not causative of, a variety of inflammatory neuropathological processes. In these cells CB 1 appears to be present at constitutive and relatively low levels while CB 2 is expressed inducibly during the inflammatory process and at relatively high levels. Immune responses during the early phase of neuropathological processes appear to involve preponderantly CB 2 , and levels and functional relevance of this receptor may be amplified as disease progresses to later stages of inflammation. The recognition that immunocytes resident within the brain express CB 2 , during the inflammatory process suggests the existence of a temporal window during which these cells may be susceptible to therapeutic manipulation through the use of CB 2 -selective agonists. That is, selective targeting of the CB 2 could result in dampening of untoward immune responses such as elicitation of a chemokine/cytokine 'storm' within the CNS that would result in breakdown of the blood-brain barrier, influx of immunocytes from peripheral non-neuronal sites, and further inflammation.
Clinical implications/applications
Cannabinoids, as ligands that signal through cannabinoid receptors, may be particularly useful as agents for therapeutic manipulation of hyperinflammatory immune responses within the CNS. These compounds are highly lipophilic and thus readily penetrate the bloodbrain barrier, a challenge that is posed to a variety of agents that have therapeutic potential. Furthermore, through the application of appropriately engineered molecules, it may be possible to specifically target CB 2 , a condition that would obviate generation of untoward psychotropic effects that could be engendered if the CB 1 were activated also. TheprincipalpotentialcellulartargetintheCNSfor these compounds -given its involvement in early stages of the inflammatory response in generation of a cascade of inflammatory factors and its expression of CB 2 -is the microglial cell. During activation, microglia, as macrophage-like cells, also upregulate an array of cell-surface receptors that may be critical in regeneration and/or degeneration of the CNS. Included among these are immunoglobulin (Ig) superfamily receptors, complement receptors, Toll-like receptors, cytokine/ chemokine receptors, and opioid receptors. These cells, in addition to expressing both the CB 1 and the CB 2 in vitro (Refs 105, 167), also produce the endocannabinoids 2-AG as well as AEA, although the latter is generated in lesser quantities (Ref. 94) . Thus, microglia appear to harbour a fully constituted system of endogenous cannabinoid ligands and cognate receptors. Activation of CB 2 on these cells appears to promote migration and proliferation. 2-AG induces migration of microglia and this occurs through the CB 2 and abnormal-CBD-sensitive receptors, which subsequently leads to activation of the extracellular-signal-regulated kinase (ERK)1 and 2 (encoded by the MAPK1 and MAPK2 genes, respectively) signal transduction pathway (Ref. 3) . Furthermore, it has been shown that microglia express CB 2 at the leading edge of lamellipodia, consistent with an involvement in cell migration. There is accumulating evidence that CB 2 also is expressed in the CNS in vivo. The expression of CB 2 in microglial, astrocyte and neuronal subpopulations has been identified in a variety of neurodegenerative disease models (Ref. 37 ). This expression of CB 2 in vivo has been attributed, in large measure, to microglia. In several neurodegenerative diseases, upregulation of microglial CB 2 has been observed ( Refs 148, 162, 168, 169, 170, 171) . In studies investigating the expression profile of FAAH and the CB 2 in postmortem brain tissues from Alzheimer disease patients, it was observed that congregated microglia associated with neuritic plaques selectively overexpressed CB 2 (Ref. 172 ). In addition, CB 2 -positive microglia have been identified dispersed within active multiple sclerosis plaques and in the periphery of chronic active plaques (Ref. 169) .
The collective findings support the concept that, in addition to CB 1 , CB 2 has a functionally relevant role in the CNS. This role appears to play out during the inflammatory process associated with a variety of neuropathies. In this context, it has been proposed that the role of the CB 2 in immunity in the CNS is primarily one that is anti-inflammatory (Ref. 173) . Since microglia exhibit phenotypic and functional properties of macrophages and inducibly express CB 2 at maximal levels when in responsive and primed states, there may be a window of functional relevance for this receptor, comparable to that for macrophages at peripheral sites. That is, antigen processing and/or chemotaxis by these cells may also be susceptible to cannabinoids acting via CB 2 .
Indeed, studies using a mouse model of GAE, a chronic progressive human infection of the CNS that is caused by the opportunistic pathogen Acanthamoeba, revealed a paucity of cells expressing the Mac-1 (CD11b) protein marker for macrophages and macrophage-like cells at focal sites containing Acanthamoeba in the brains of infected mice treated with D Emerging role of the cannabinoid receptor CB
